Eversept Partners LP Sells 899,018 Shares of Vera Therapeutics, Inc. $VERA

Eversept Partners LP reduced its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 29.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,173,286 shares of the company’s stock after selling 899,018 shares during the quarter. Vera Therapeutics accounts for about 4.6% of Eversept Partners LP’s investment portfolio, making the stock its 4th largest holding. Eversept Partners LP’s holdings in Vera Therapeutics were worth $87,431,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after buying an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Vera Therapeutics by 22.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after acquiring an additional 17,907 shares during the last quarter. Jane Street Group LLC grew its holdings in Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after acquiring an additional 62,678 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Vera Therapeutics by 550.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after purchasing an additional 262,805 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Vera Therapeutics by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after purchasing an additional 825 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 0.8%

Shares of Vera Therapeutics stock opened at $35.18 on Tuesday. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of -6.35 and a beta of 0.92. Vera Therapeutics, Inc. has a twelve month low of $19.07 and a twelve month high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The business’s 50 day simple moving average is $37.02 and its 200-day simple moving average is $40.01.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the business posted ($0.81) earnings per share. Equities research analysts forecast that Vera Therapeutics, Inc. will post -6.37 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,250 shares of company stock valued at $3,337,770 in the last quarter. Company insiders own 15.90% of the company’s stock.

Analyst Ratings Changes

VERA has been the topic of a number of research analyst reports. HC Wainwright increased their target price on Vera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Evercore set a $91.00 price objective on shares of Vera Therapeutics in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.58.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.